{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:11:32Z","timestamp":1773321092009,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-037-076-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-037-076-MY3"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["S11312"],"award-info":[{"award-number":["S11312"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jfma.2025.10.028","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T19:19:10Z","timestamp":1761419950000},"page":"S113-S117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S2","title":["HCV elimination in hyperendemic areas: Experiences in Taiwan"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2296-3054","authenticated-orcid":false,"given":"Chia-Yen","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-421X","authenticated-orcid":false,"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2025.10.028_bib1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib2","first-page":"646","article-title":"Real-world effectiveness and tolerability of interferon-free direct-acting antiviral for 15,849 patients with chronic hepatitis C: a multinational cohort study","volume":"12","author":"Ji","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib3","series-title":"Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis","year":"2016"},{"key":"10.1016\/j.jfma.2025.10.028_bib4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S2468-1253(25)00068-8","article-title":"A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles","volume":"10","author":"Hiebert-Suwondo","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib5","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/kjm2.12552","article-title":"Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in tzukuan, a hyperendemic area of southern Taiwan","volume":"38","author":"Tsai","year":"2022","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2025.10.028_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000087271","article-title":"Treatment of chronic hepatitis C in southern Taiwan","volume":"49","author":"Chuang","year":"2006","journal-title":"Intervirology"},{"key":"10.1016\/j.jfma.2025.10.028_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7883\/yoken1952.45.165","article-title":"High prevalence of hepatitis C virus infection in aborigines in Taiwan","volume":"45","author":"Wu","year":"1992","journal-title":"Jpn J Med Sci Biol"},{"key":"10.1016\/j.jfma.2025.10.028_bib8","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1440-1746.2009.05789.x","article-title":"Treatment of chronic hepatitis C in Asia: when East meets west","volume":"24","author":"Yu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib9","series-title":"Taiwan hepatitis C policy guidelines 2018\u20132025","year":"2019"},{"key":"10.1016\/j.jfma.2025.10.028_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0038-1666841","article-title":"The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations","volume":"38","author":"Lazarus","year":"2018","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jfma.2025.10.028_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.35772\/ghm.2021.01064","article-title":"Taiwan accelerates its efforts to eliminate hepatitis C","volume":"3","author":"Chien","year":"2021","journal-title":"Glob Health Med"},{"issue":"Suppl 3","key":"10.1016\/j.jfma.2025.10.028_bib12","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1093\/infdis\/jiad016","article-title":"Policy and strategy for hepatitis C virus elimination at the national level: experience in Taiwan","volume":"228","author":"Chien","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2025.10.028_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhep.2008.03.016","article-title":"Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study","volume":"49","author":"Dai","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1607-551X(10)70073-5","article-title":"Viral hepatitis infections in southern Taiwan: a multicenter community-based study","volume":"26","author":"Yang","year":"2010","journal-title":"Kaohsiung J Med Sci"},{"issue":"Suppl 3","key":"10.1016\/j.jfma.2025.10.028_bib15","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/infdis\/jiac446","article-title":"HCV microelimination for high-risk special populations","volume":"228","author":"Huang","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2025.10.028_bib16","first-page":"605","article-title":"Incidence of hepatitis C infection in a hepatitis C endemic township in southern Taiwan","volume":"13","author":"Lu","year":"1997","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2025.10.028_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jmii.2023.04.012","article-title":"A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co-V2 pandemic","volume":"56","author":"Huang","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jfma.2025.10.028_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042861","article-title":"Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT study in Taiwan","volume":"11","author":"Tsai","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jfma.2025.10.028_bib19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/JCMA.0000000000000561","article-title":"The association between hepatitis C virus infection and renal function","volume":"84","author":"Gantumur","year":"2021","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jfma.2025.10.028_bib20","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1186\/s12889-024-20331-0","article-title":"Coincidence of HCV and chronic kidney disease: a systematic review and meta-analysis","volume":"24","author":"Nawaz","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jfma.2025.10.028_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jhep.2013.09.023","article-title":"High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients","volume":"60","author":"Yu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.ajkd.2006.07.004","article-title":"Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region","volume":"48","author":"Di Napoli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2025.10.028_bib23","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jfma.2020.04.002","article-title":"2020 Taiwan consensus statement on the management of hepatitis C: part (II) special populations","volume":"119","author":"Yu","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.10.028_bib24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2020.10.023","article-title":"DAA therapy in hepatitis C in patients with chronic kidney disease: new information for GFR category G4 and G5","volume":"20","author":"Dai","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.kint.2019.10.030","article-title":"Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients","volume":"97","author":"Huang","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2025.10.028_bib26","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1136\/gutjnl-2020-323277","article-title":"Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C)","volume":"70","author":"Yu","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2025.10.028_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12072-014-9527-7","article-title":"Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics","volume":"8","author":"Huang","year":"2014","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2025.10.028_bib28","series-title":"Bloodborne viral and sexually transmissible infections in Aboriginal and Torres strait Islander people: annual surveillance report 2017","year":"2017"},{"key":"10.1016\/j.jfma.2025.10.028_bib29","article-title":"Distribution of hepatitis C risk factors and HCV treatment outcomes among Central Canadian Aboriginal","volume":"2016","author":"Parmar","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib30","first-page":"241","article-title":"Risk factors of hepatitis C virus infection in a Taiwanese aboriginal community","volume":"12","author":"Chang","year":"1996","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2025.10.028_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s150100070036","article-title":"Ethnic and geographic variations in the prevalence of hepatitis A, B and C among aboriginal villages in Hualien, Taiwan","volume":"28","author":"Lin","year":"2000","journal-title":"Infection"},{"key":"10.1016\/j.jfma.2025.10.028_bib32","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep4.1531","article-title":"Secular trends and geographic maps of hepatitis C virus infection among 4 million blood donors in Taiwan from 1999 to 2017","volume":"4","author":"Chen","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jfma.2025.10.028_bib33","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jmii.2023.01.014","article-title":"Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan: a multi-center collaborative care model","volume":"56","author":"Lo","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jfma.2025.10.028_bib34","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.3390\/ijerph19063269","article-title":"Liver disease screening and hepatitis C virus elimination in Taiwan rural indigenous townships: village-by-village screening and linking to outreach hepatology care","volume":"19","author":"Tien","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jfma.2025.10.028_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"Blach","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100685","article-title":"The impact of COVID-19 on the cascade of care of HCV in the US and China","volume":"27","author":"Yeo","year":"2022","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.880435","article-title":"The negative impact of COVID-19 in HCV, HIV, and HPV surveillance programs during the different pandemic waves","volume":"10","author":"Romero-Hern\u00e1ndez","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.jfma.2025.10.028_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa225","article-title":"222 days without COVID in Taiwan: what are the reasons for this success?","volume":"28","author":"Dai","year":"2021","journal-title":"J Travel Med"},{"key":"10.1016\/j.jfma.2025.10.028_bib39","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/v14081637","article-title":"Collaborative referral model to achieve hepatitis C micro-elimination in methadone maintenance treatment patients during the COVID-19 pandemic","volume":"14","author":"Tai","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jfma.2025.10.028_bib40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3390\/v15040827","article-title":"Collaborative referral model for hepatitis C screening and treatment in a remote mountainous region of Taiwan during the COVID-19 pandemic","volume":"15","author":"Tai","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jfma.2025.10.028_bib41","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/kjm2.12552","article-title":"Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan","volume":"38","author":"Tsai","year":"2022","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2025.10.028_bib42","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.3390\/ijerph20054415","article-title":"Barriers and facilitators to hepatitis C virus (HCV) treatment for Aboriginal and Torres Strait Islander peoples in rural South Australia: a service providers' perspective","volume":"20","author":"Lim","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jfma.2025.10.028_bib43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1071\/PY18024","article-title":"Delivering the hepatitis C cure to Aboriginal people: documenting the perspectives of one Aboriginal Health Service","volume":"24","author":"Wallace","year":"2018","journal-title":"Aust J Prim Health"},{"key":"10.1016\/j.jfma.2025.10.028_bib44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/14461242.2015.1126187","article-title":"Multiple stigmas, shame and historical trauma compound the experience of Aboriginal Australians living with hepatitis C","volume":"25","author":"Treloar","year":"2016","journal-title":"Health Sociol Rev"},{"key":"10.1016\/j.jfma.2025.10.028_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103247","article-title":"Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: a knowledge synthesis","volume":"96","author":"Amoako","year":"2021","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jfma.2025.10.028_bib46","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000690","article-title":"Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jfma.2025.10.028_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15756","article-title":"Cost-effectiveness of universal and targeted hepatitis C virus screening in the United States","volume":"3","author":"Tatar","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jfma.2025.10.028_bib48","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1080\/14767058.2021.1949442","article-title":"A cost-effectiveness analysis of universal hepatitis C screening in all United States pregnancies","volume":"35","author":"Susich","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.jfma.2025.10.028_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103345","article-title":"Implementing opt-out hepatitis C virus (HCV) screening in Canadian provincial prisons: a model-based cost-effectiveness analysis","volume":"96","author":"Duchesne","year":"2021","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jfma.2025.10.028_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3350\/cmh.2021.0236","article-title":"A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: a societal perspective","volume":"28","author":"Kim","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib51","article-title":"Universal screening for HCV infection in China: an effectiveness and cost-effectiveness analysis","volume":"6","author":"Zhou","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jfma.2025.10.028_bib52","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/hepr.13478","article-title":"Estimating the cost-effectiveness of screening for hepatitis C virus infection in Japan","volume":"50","author":"Nagai","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.10.028_bib53","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib54","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2018.05.027","article-title":"Assessing the cost-effectiveness of hepatitis C screening strategies in France","volume":"69","author":"Deuffic-Burban","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.10.028_bib55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/13814788.2022.2056161","article-title":"Chronic hepatitis C: diagnosis and treatment made easy","volume":"28","author":"Abu-Freha","year":"2022","journal-title":"Eur J Gen Pract"},{"key":"10.1016\/j.jfma.2025.10.028_bib56","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3390\/v15030661","article-title":"The cascade of care for hepatitis C treatment in Rwanda: a retrospective cohort study of the 2017-2019 mass screening and treatment campaign","volume":"15","author":"Nisingizwe","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jfma.2025.10.028_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/kjm2.70060","article-title":"A point-of-care model for hepatitis C elimination in remote islands of Taiwan","author":"Lin","year":"2025","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2025.10.028_bib58","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jfma.2019.07.011","article-title":"Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan","volume":"119","author":"Wang","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.10.028_bib59","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","article-title":"2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population","volume":"119","author":"Yu","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.10.028_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12876-023-02665-y","article-title":"Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Gastroenterol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462500573X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462500573X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:56:49Z","timestamp":1773259009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966462500573X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":60,"alternative-id":["S092966462500573X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.10.028","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HCV elimination in hyperendemic areas: Experiences in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}